Vnitr Lek 2023, 69(1):57-63 | DOI: 10.36290/vnl.2023.008

News in cardiology

Jan Václavík
Interní a kardiologická klinika Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity

The article summarizes new advances in cardiology published in 2022, which have an impact to everyday practice of not only internists and cardiologists. The administration of polypill to patients after myocardial infarction (SECURE study), early pharmacotherapy of hypertension in pregnant women with blood pressure exceeding 140/90 mmHg (CHAP study), or the administration of dapagliflozin to patients with heart failure with preserved or mildly reduced ejection fraction (DELIVER study) have been shown to be effective. Patients with heart failure do not have to limit their sodium intake (SODIUM-HF study), on the contrary, they benefit from up-titration of guideline-recommended drugs to the maximum tolerated doses as quickly as possible (STRONG-HF study). For antihypertensives, it does not matter whether they are taken in the morning or in the evening (TIME study), nor has there been found any difference in the incidence of cardiovascular events with hydrochlorothiazide and chlortalidone (DCP study). In patients with increased cardiovascular risk, highly sensitive troponin should be measured before non-cardiac surgery as well as 24 and 48 hours after surgery to detect perioperative myocardial infarction. Different blood pressure and oxygenation targets in patients after resuscitation for out-of-hospital cardiac arrest do not affect the outcomes of their treatment.

Keywords: update, cardiology, arterial hypertension, hypertension during pregnancy, myocardial infarction, heart failure.

Accepted: February 6, 2023; Published: February 17, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J. News in cardiology. Vnitr Lek. 2023;69(1):57-63. doi: 10.36290/vnl.2023.008.
Download citation

References

  1. Castellano JM, Pocock SJ, Bhatt DL, et al. SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-977. Go to original source... Go to PubMed...
  2. Mackenzie IS, Rogers A, Poulter NR, et al. Lancet. 2022 Oct 22;400(10361):1417-1425. Go to original source... Go to PubMed...
  3. Tita AT, Szychowski JM, Boggess K, et al. Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781-1792. Go to original source... Go to PubMed...
  4. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non‑cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924. Go to original source... Go to PubMed...
  5. Kjaergaard J, Møller JE, Schmidt H, et al. Blood‑Pressure Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022 Oct 20;387(16):1456-1466. Go to original source... Go to PubMed...
  6. Schmidt H, Kjaergaard J, Hassager C, et al. Oxygen Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022 Oct 20;387(16):1467-1476. Go to original source... Go to PubMed...
  7. Solomon SD, McMurray JJV, Claggett B, et al. DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. Go to original source... Go to PubMed...
  8. Ezekowitz JA, Colin‑Ramirez E, Ross H, et al. SODIUM‑HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM‑HF): an international, open‑label, randomised, controlled trial. Lancet. 2022 Apr 9;399(10333):1391-1400. Erratum in: Lancet. 2022 Oct 8;400(10359):1194. Go to original source... Go to PubMed...
  9. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up‑titration of guideline‑directed medical therapies for acute heart failure (STRONG‑HF): a multinational, open‑label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. Go to original source... Go to PubMed...
  10. Ishani A, Cushman WC, Leatherman SM, et al. Diuretic Comparison Project Writing Group. Chlorthalidone vs. Hydrochlorothiazide for Hypertension‑Cardiovascular Events. N Engl J Med. 2022 Dec 29;387(26):2401-2410. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.